155 related articles for article (PubMed ID: 31876792)
1. Experience of Using Adrenocorticotropic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series.
Berkovich R
Clin Neuropharmacol; 2020; 43(1):7-14. PubMed ID: 31876792
[TBL] [Abstract][Full Text] [Related]
2. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
3. [Effects of intravenous methylprednisolone pulse therapy on recurrent optic neuritis associated with aquaporin 4 antibody seropositive neuromyelitis optica].
Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):509-513. PubMed ID: 32842332
[No Abstract] [Full Text] [Related]
4. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
Abboud H; Petrak A; Mealy M; Sasidharan S; Siddique L; Levy M
Mult Scler; 2016 Feb; 22(2):185-92. PubMed ID: 25921047
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
[TBL] [Abstract][Full Text] [Related]
7. [Effects of intravenous methylprednisolone pulse therapy on optic neuritis associated with AQP4 antibody seropositive neuromyelitis optica].
Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
Zhonghua Yan Ke Za Zhi; 2019 Mar; 55(3):180-185. PubMed ID: 30841684
[No Abstract] [Full Text] [Related]
8. Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica.
Guo S; Jiang H; Jiang L; Peng J; Liu H; Wang J; Wei W
Sci Rep; 2021 Nov; 11(1):22229. PubMed ID: 34782653
[TBL] [Abstract][Full Text] [Related]
9. Radiomics Analysis of DTI Data to Assess Vision Outcome After Intravenous Methylprednisolone Therapy in Neuromyelitis Optic Neuritis.
Tian Y; Liu Z; Tang Z; Li M; Lou X; Dong E; Liu G; Wang Y; Wang Y; Bian X; Wei S; Tian J; Ma L
J Magn Reson Imaging; 2019 May; 49(5):1365-1373. PubMed ID: 30252996
[TBL] [Abstract][Full Text] [Related]
10. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.
Songthammawat T; Srisupa-Olan T; Siritho S; Kittisares K; Jitprapaikulsan J; Sathukitchai C; Prayoonwiwat N
Mult Scler Relat Disord; 2020 Feb; 38():101506. PubMed ID: 31731214
[TBL] [Abstract][Full Text] [Related]
11. Adrenocorticotropic hormone
Berkovich R; Bakshi R; Amezcua L; Axtell RC; Cen SY; Tauhid S; Neema M; Steinman L
Ther Adv Neurol Disord; 2017 Jan; 10(1):3-17. PubMed ID: 28450891
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
Yamasaki R; Matsushita T; Fukazawa T; Yokoyama K; Fujihara K; Ogino M; Yokota T; Miyamoto K; Niino M; Nomura K; Tomioka R; Tanaka M; Kawachi I; Ohashi T; Kaida K; Matsui M; Nakatsuji Y; Ochi H; Fukaura H; Kanda T; Nagaishi A; Togo K; Mizusawa H; Murai H; Kira J
Mult Scler; 2016 Sep; 22(10):1337-48. PubMed ID: 26564994
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Altintas A; Karabudak R; Balci BP; Terzi M; Soysal A; Saip S; Tuncer Kurne A; Uygunoglu U; Nalbantoglu M; Gozubatik Celik G; Isik N; Celik Y; Gokcay F; Duman T; Boz C; Yucesan C; Mangan MS; Celebisoy N; Diker S; Colpak Isikay I; Kansu T; Siva A
Neurologist; 2015 Oct; 20(4):61-6. PubMed ID: 26468870
[TBL] [Abstract][Full Text] [Related]
14. Acute bilateral cerebral infarction in the presence of neuromyelitis optica spectrum disorder: A case report.
Wang ZY; Wang M; Guo JJ; Gao YL; Yu XF
Medicine (Baltimore); 2020 Oct; 99(40):e22616. PubMed ID: 33019482
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of neuromyelitis optica].
Fujihara K
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):129-35. PubMed ID: 22576570
[TBL] [Abstract][Full Text] [Related]
16. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
[TBL] [Abstract][Full Text] [Related]
17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
20. Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
Miao J; Aboagye DE; Chulpayev B; Liu L; Ishkanian G; Kolanuvada B; Alaie D; Petrillo RL
Am J Case Rep; 2018 Jan; 19():41-46. PubMed ID: 29321467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
